fore, The question I hear most often from patients who are ready to start a weight loss medication is not whether these drugs work. After the last few years of trial data and clinical experience, that conversation has largely shifted. The question now is which one. Semaglutide or tirzepatide. Wegovy or Zepbound. And what actually differs between them beyond the name on the box.
It is a reasonable question, and the honest answer is that both medications represent a genuine step forward from what came before them, but they are not identical. They work through related but distinct mechanisms, they produce different average results in the clinical trials, and for individual patients, the choice between them often comes down to factors that have as much to do with access and tolerability as with pharmacology. Here is how I think through that comparison in practice.
Table of Contents
What Both Medications Have in Common
Semaglutide (sold as Wegovy for weight loss) and tirzepatide (sold as Zepbound for weight loss) both belong to a class of medications that work through incretin hormone pathways. The basic idea is this: your gut naturally produces hormones after you eat that signal to your brain you are full, slow gastric emptying so food moves through your stomach more gradually, and help your body handle blood sugar more effectively. Both of these medications activate those pathways on a sustained basis, which is why people on them report feeling genuinely less hungry, not just less interested in food as a matter of willpower, but biologically less driven to eat.
Both are administered by weekly subcutaneous injection. Therefore, both are started at a low dose and increased gradually over several months to reduce gastrointestinal side effects. Both require a prescription and ongoing prescriber oversight. And both produce results in clinical trials that were not achievable with the weight loss medications that came before them.
Where the Mechanisms Diverge
Semaglutide is a GLP-1 receptor agonist. GLP-1 stands for glucagon-like peptide-1, one of the main incretin hormones your gut releases after eating. Semaglutide mimics this hormone specifically, binding to GLP-1 receptors and producing the fullness and blood sugar signaling those receptors are designed to trigger.
Tirzepatide is a dual agonist. It activates both GLP-1 receptors and GIP receptors, where GIP stands for glucose-dependent insulinotropic polypeptide, a second incretin hormone. Activating both pathways simultaneously appears to produce a more pronounced effect on appetite suppression and metabolic signaling than activating GLP-1 alone. That is the core mechanistic reason why the tirzepatide trial data tends to show larger average results.
The practical significance of this difference is that tirzepatide is essentially hitting two levers at once. Whether that translates into meaningfully better outcomes for a specific patient depends on a lot of individual factors, but it does show up clearly in the population-level data.
What the Trial Data Shows
The STEP 1 trial for semaglutide, published in the New England Journal of Medicine in 2021, showed an average body weight loss of 14.9 percent over 68 weeks. For a 220-pound person, that is roughly 33 pounds on average. That was a significant result — no weight loss medication had produced anything close to that in prior trials.
The SURMOUNT-1 trial for tirzepatide, published in 2022, showed results that were larger across all doses. At the highest dose studied (15 mg weekly), participants lost an average of 20.9 percent of body weight over 72 weeks. For that same 220-pound person, that is roughly 46 pounds. At the intermediate doses, results were lower, but still exceeded semaglutide’s STEP 1 average at most comparisons.
These are population averages, which means there is meaningful individual variation in both directions. Some patients on semaglutide lose significantly more than 14.9 percent. Some on tirzepatide lose less than the trial average. The trials also used different populations and slightly different protocols, so direct head-to-head comparisons should be interpreted carefully. What they establish clearly is that tirzepatide produced larger average losses in its trials, and that both produced results that place them in a different category from anything that came before.
Side Effects: How They Compare
The side effect profiles of semaglutide and tirzepatide are broadly similar, which makes sense given that both work through incretin pathways. Nausea is the most common complaint with both, particularly in the first few weeks of each dose increase. Most patients describe it as manageable when the titration is done slowly. Constipation, occasional vomiting, and early-treatment fatigue are also reported with both medications.
In the trial data, tirzepatide showed slightly higher rates of gastrointestinal side effects at its higher doses compared to semaglutide, which is not surprising given that it is activating an additional receptor pathway. Whether this is a clinically meaningful difference for a given patient depends on how they respond to dose increases. Some patients who had difficulty tolerating semaglutide have reported doing well on tirzepatide, and vice versa, which suggests individual variation matters more than population-level averages in predicting tolerability.
Both medications carry a black box warning regarding a potential association with thyroid C-cell tumors based on animal studies. Anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 should not take either medication. This is a genuine contraindication, not a minor footnote. The clinical relevance of the animal data in humans remains under study, but it is a conversation every patient should have with their prescriber before starting.
Cost, Coverage, and Access
Both medications are expensive at list price without insurance coverage. Wegovy (semaglutide) and Zepbound (tirzepatide) both have list prices that can exceed one thousand dollars per month without coverage. Both manufacturers offer savings programs that significantly reduce out-of-pocket cost for commercially insured patients who qualify, but navigating those programs takes effort, and coverage decisions by insurance plans continue to shift.
For patients trying to understand the full cost and access landscape for these medications, including which programs are currently available and what each medication is typically prescribed for, WeightLossPills.com provides current comparisons of both medications including coverage guidance and savings program details.
In practice, I have seen insurance coverage be the deciding factor between which medication a patient starts on more often than clinical preference. If one medication is covered and the other is not, that tends to settle the question quickly, regardless of what the trial data shows about average results. The best medication for a patient is the one they can actually afford to stay on.
Which One Should You Choose?
If the question were purely about which medication produces the largest average result in clinical trials, tirzepatide wins that comparison. The SURMOUNT-1 data is larger than the STEP 1 data, and the dual mechanism gives it a plausible biological reason for that difference.
But that is rarely the only question worth asking. Semaglutide has a longer track record — it was approved earlier and there is more long-term real-world data on it. Some patients have a strong clinical reason to prefer one over the other based on their specific metabolic profile or other medications they are taking. Insurance coverage, as noted, often decides things before pharmacology gets a chance to weigh in.
What I tell patients is this: both of these medications are producing results that were not available in this category before, and both are meaningfully better than the alternatives. If you have access to tirzepatide and no clinical reason to avoid it, the trial data gives you reason to think you may see larger results. If semaglutide is what your insurance covers or what your prescriber is more experienced with, the difference in average trial outcomes should not drive you to stay unmedicated while you fight for coverage of the other one.
The comparison that matters most is not semaglutide versus tirzepatide. It is either of these medications versus what you were doing before. On that comparison, both win convincingly.
A Note on What Both Medications Require
Neither medication does the work independently. This point gets lost in the framing of comparisons, where the focus tends to be on which drug produces more weight loss. Both semaglutide and tirzepatide work by reducing hunger signals, which makes it easier to eat less and make different choices. They do not bypass the body’s need to operate at a caloric deficit. They make that deficit easier to sustain, which is why results look so different from willpower-based approaches.
Patients who get the best results from either medication tend to be those who use the reduced hunger as an opportunity to build different habits, who maintain consistent prescriber contact for dose adjustments, and who have realistic expectations about the timeline. Weight loss on these medications is real and clinically significant. It is also gradual, it plateaus, and it requires active management.
The question of which medication to choose is worth asking. But the more important question is whether you are set up to use either one well — with appropriate follow-up, realistic expectations, and a prescriber who knows what they are managing. That combination produces better outcomes than any dose comparison between two drugs.
The Bottom Line
Semaglutide and tirzepatide are both effective, both represent a meaningful advance over what came before them, and both require medical oversight to use well. Tirzepatide shows larger average results in its clinical trials. Semaglutide has a longer track record. The right choice depends on your insurance, your prescriber’s experience, your individual tolerance, and sometimes just which one you can get.
If you are having this conversation with your doctor, the goal should be to understand both options clearly enough to have a productive discussion about which makes sense for your specific situation. Neither choice is wrong. Starting is almost always more valuable than waiting for the perfect comparison to resolve itself.
Dr. Quoc Dang
Medical Director, WeightLossPills.com
